746
Views
12
CrossRef citations to date
0
Altmetric
Brief report

An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

, , &
Pages 108-114 | Accepted 14 Sep 2012, Published online: 10 Oct 2012

References

  • McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
  • Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14
  • Lefebvre P, Duh MS, Buteau S, et al. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol 2006;17:3497-502
  • National Institute for Health and Clinical Excellence (NICE). Anaemia management in people with chronic kidney disease. 2011. http://www.nice.org.uk/CG114. Accessed May 6, 2011
  • O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum 2008;21:12-9
  • Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6
  • Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161-7
  • Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61
  • Valderrabano F, Horl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100
  • Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23
  • Macdougall IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 1989;299:157-8
  • Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999;69:S61-6
  • Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-c62
  • Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(2 Suppl):ii1-47
  • Mircescu G, Garneata L, Capusa C, et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006;21:120-4
  • Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-56
  • Bager P, Dahlerup JF. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis 2010;4:427-30
  • Szucs TD, Blank PR, Schwenkglenks M. Health economic impact of intravenous iron supplementation in anaemia treatment with erythropoiesis-stimulating agents. 2009. Poster presented at European Hematology Association Congress (0135), Berlin, Germany
  • Szucs TD, Blank PR, Schwenkglenks M, et al. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology 2011;81:45-9
  • Tagboto S, Cropper L, Turner J, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Ren Care 2009;35:18-23
  • Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-9
  • Vifor Pharma. Ferinject summary of product characteristics. 2011. http://www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinject=(ferric=carboxymaltose)/. Accessed March 19, 2010
  • NHS Careers. NHS pay - agenda for change - pay rates. 2011. http://www.nhscareers.nhs.uk/details/default.aspx?Id=766. Accessed May 6, 2011
  • British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 62. London: BMJ Group and Pharmaceutical Press, 2011
  • King's College Hospital data: 2010
  • Transport for London. Fares. 2011. http://www.tfl.gov.uk/tickets/14416.aspx. Accessed June 27, 2011
  • Pugh-Clarke K, Cooper L, Turner J, et al. An evidence-based approach to anaemia management in predialysis chronic kidney disease. J Ren Care 2009;35(2 Suppl):29-31
  • Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009;71:125-9
  • Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011;7:103-13
  • Brock E, Braunofer P, Troxler J, et al. Real-life budget impact (BI) of parenteral iron treatment of iron deficiency in Switzerland. 2010. Poster presented at ISPOR (PSY12). Prague, Czech Republic
  • Office for National Statistics. Labour market statistics April 2011. 2011. http://www.ons.gov.uk/ons/search/index.html?pageSize=50&newquery=Labour+Statistics+bulletin+April. Accessed May 6, 2011

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.